The pharmaceutical industry has witnessed an unprecedented wave of mergers and acquisitions $($M&A$)$ in the last $15$ years, reshaping its landscape and dynamics. This report critically analyzes the driving forces behind this transformation, with a particular focus on synergies, tax considerations, research costs, marketing, and other drivers that have contributed to this phenomenon.